2-73 is still along way off from compassionate use. The pivotal trial data will have to show the results that the media is covering in order for that to happen. And considering the phase 2/3 won't start until later this year, prelim data may not come out until the summer of 2017, if not later. Sarepta is a very recent example of how despite patients and doctors asking for the drug, the FDA will still say no. The 2-73 data, which includes a questionnaire from caregivers, has to support the anecdotal evidence.
News 
Market Data 
Discover 
